3C
SUPN icon

361 Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

361 Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-27,880
Closed -$1.67M – 396
2018
Q2 		$1.67M Sell
27,880
-9,639
-26% -$499K 0.38% 115
2018
Q1 		$1.72M Buy
+37,519
New +$1.57M 0.43% 58

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

361 Capital's SUPN Position: Q3 2018 in Review

361 Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 27,880 shares — an estimated $1.67M sold.

361 Capital first reported a position in SUPN in Q1 2018 and held it in 2 quarters. The position peaked at $1.72M in Q1 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • 361 Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • 361 Capital sold 27,880 Supernus Pharmaceuticals shares in Q3 2018, an estimated $1.67M.
  • 361 Capital first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • 361 Capital's Supernus Pharmaceuticals position peaked at $1.72M in Q1 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on 361 Capital's 13F filing for Q3 2018, filed 13 Nov 2018.